In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: Recovery of cerebral metabolism with acute levodopa treatment

Journal of Neurochemistry

Volumn 127, Issue 3, 2013, Pages 365-377

  Bagga, Puneet ^a   Chugani, Anup N ^a   Varadarajan, Komanduri S ^a   Patel, Anant B ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

GABA; glutamate; metabolism; MRI; olfactory bulb; striatum

Indexed keywords

4 AMINOBUTYRIC ACID; INOSITOL; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; ENERGY METABOLISM; ENERGY TRANSFER; GLUCOSE OXIDATION; GRIP STRENGTH; IN VIVO STUDY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY BULB; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

GABA; GLUTAMATE; METABOLISM; MRI; OLFACTORY BULB; STRIATUM;

ACETATES; ALGORITHMS; ANIMALS; ANTIPARKINSON AGENTS; BLOOD GLUCOSE; BRAIN CHEMISTRY; ENERGY METABOLISM; GLUTAMATES; HAND STRENGTH; IMAGE PROCESSING, COMPUTER-ASSISTED; LEVODOPA; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; MPTP POISONING; NEOSTRIATUM; OXIDATION-REDUCTION; PARKINSON DISEASE, SECONDARY; PSYCHOMOTOR PERFORMANCE; RADIOPHARMACEUTICALS;

MUS;

EID: 84886102178     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12407     Document Type: Article

References (67)

1. Achar V. S., Welch K. M., Chabi E., Bartosh K., and, Meyer J. S., (1976) Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease. Neurology 26, 777-780.
2. Alam M., and, Schmidt W. J., (2004) Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease. Physiol. Behav. 83, 395-400.
3. Alexander G. E., (1994) Basal ganglia-thalamocortical circuits: their role in control of movements. J. Clin. Neurophysiol. 11, 420-431.
4. Alexander J. J., Zwingmann C., and, Quigg R., (2005) MRL/lpr mice have alterations in brain metabolism as shown with [1H-13C] NMR spectroscopy. Neurochem. Int. 47, 143-151.
5. Aponso P. M., Faull R. L., and, Connor B., (2008) Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience 151, 1142-1153.
6. Araki T., Mikami T., Tanji H., Matsubara M., Imai Y., Mizugaki M., and, Itoyama Y., (2001) Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur. J. Pharm. Sci. 12, 231-238.
7. Aroniadou-Anderjaska V., Zhou F. M., Priest C. A., Ennis M., and, Shipley M. T., (2000) Tonic and synaptically evoked presynaptic inhibition of sensory input to the rat olfactory bulb via GABA(B) heteroreceptors. J. Neurophysiol. 84, 1194-1203.
8. Badar-Goffer R. S., Bachelard H. S., and, Morris P. G., (1990) Cerebral metabolism of acetate and glucose studied by 13C-n.m.r. spectroscopy. A technique for investigating metabolic compartmentation in the brain. Biochem. J. 266, 133-139.
9. Bagga P., and, Patel A. B., (2012) Regional cerebral metabolism in mouse under chronic manganese exposure: implications for manganism. Neurochem. Int. 60, 177-185.
10. Bagga P., Chugani A. N., Kumar M. S., and, Patel A. B., (2013) Dietary restriction recovers cerebral activity in Pitx3 knockout mouse model of Parkinson's disease, in Proc. Intl. Soc. Mag. Reson. Med., vol. 20. Salt Lake City, UT, 1976.
11. Beyer M. K., Alves G., Hwang K. S., et al,. (2013) Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson's disease. Mov. Disord. 28, 302-310.
12. Blandini F., and, Armentero M. T., (2012) Animal models of Parkinson's disease. FEBS J. 279, 1156-1166.
13. Blesa J., Phani S., Jackson-Lewis V., and, Przedborski S., (2012) Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol. 2012, 845618.
14. Block M. L., and, Hong J. S., (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 77-98.
15. Block M. L., and, Hong J. S., (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans. 35, 1127-1132.
16. Borghammer P., Cumming P., Ostergaard K., Gjedde A., Rodell A., Bailey C. J., and, Vafaee M. S., (2012a) Cerebral oxygen metabolism in patients with early Parkinson's disease. J. Neurol. Sci. 313, 123-128.
17. Borghammer P., Hansen S. B., Eggers C., et al,. (2012b) Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurol. Scand. 125, 303-310.
18. Brodoehl S., Klingner C., Volk G. F., Bitter T., Witte O. W., and, Redecker C., (2012) Decreased olfactory bulb volume in idiopathic Parkinson's disease detected by 3.0-tesla magnetic resonance imaging. Mov. Disord. 27, 1019-1025.
19. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P. J., Di Paolo T., and, Bedard P. J., (2000) Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47, S70-S78.
20. Chassain C., Bielicki G., Durand E., Lolignier S., Essafi F., Traore A., and, Durif F., (2008) Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse. J. Neurochem. 105, 874-882.
21. 1H MRS in the MPTP-intoxicated mouse. NMR Biomed. 23, 547-553.
22. Contin M., and, Martinelli P., (2010) Pharmacokinetics of levodopa. J. Neurol. Sci. 257, S253-S261.
23. Coune P. G., Craveiro M., Gaugler M. N., Mlynarik V., Schneider B. L., Aebischer P., and, Gruetter R., (2013) An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and alpha-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker. NMR Biomed. 26, 43-50.
24. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., and, Czlonkowski A., (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5, 137-143.
25. Dalaker T. O., Zivadinov R., Ramasamy D. P., Beyer M. K., Alves G., Bronnick K. S., Tysnes O. B., Aarsland D., and, Larsen J. P., (2011) Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov. Disord. 26, 297-301.
26. Deelchand D. K., Shestov A. A., Koski D. M., Ugurbil K., and, Henry P. G., (2009) Acetate transport and utilization in the rat brain. J. Neurochem. 109 (Suppl 1), 46-54.
27. Doty R. L., (2012) Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 8, 329-339.
28. Emir U. E., Tuite P. J., and, Oz G., (2012) Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS ONE 7, e30918.
29. Eyjolfsson E. M., Nilsen L. H., Kondziella D., Brenner E., Haberg A., and, Sonnewald U., (2011) Altered 13C glucose metabolism in the cortico-striato-thalamo-cortical loop in the MK-801 rat model of schizophrenia. J. Cereb. Blood Flow Metab. 31, 976-985.
30. Fitzpatrick S. M., Hetherington H. P., Behar K. L., and, Shulman R. G., (1990) The flux from glucose to glutamate in the rat brain in vivo as determined by 1H-observed, 13C-edited NMR spectroscopy. J. Cereb. Blood Flow Metab. 10, 170-179.
31. Frahm J., Michaelis T., Merboldt K. D., Hanicke W., Gyngell M. L., Chien D., and, Bruhn H., (1989) Localized NMR spectroscopy in vivo. Progress and problems. NMR Biomed. 2, 188-195.
32. Galanaud D., Chinot O., Nicoli F., et al,. (2003) Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J. Neurosurg. 98, 269-276.
33. Gazewood J. D., Richards D. R., and, Clebak K., (2013) Parkinson disease: an update. Am. Fam. Physician 87, 267-273.
34. Gluck M. R., Youngster S. K., Ramsay R. R., Singer T. P., and, Nicklas W. J., (1994) Studies on the characterization of the inhibitory mechanism of 4'-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles. J. Neurochem. 63, 655-661.
35. 13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed. 16, 339-357.
36. 13C]-NMR spectroscopy. Magn. Reson. Med. 49, 37-46.
37. Halasz N., Hokfelt T., Ljungdahl A., Johansson O., and, Goldstein M., (1977) Dopamine neurons in the olfactory bulb. Adv. Biochem. Psychopharmacol. 16, 169-177.
38. 13C] NMR spectroscopy. J. Neurochem. 82, 857-866.
39. Hornykiewicz O., (2010) A brief history of levodopa. J. Neurol. 257, S249-S252.
40. Kim S. U., and, de Vellis J., (2005) Microglia in health and disease. J. Neurosci. Res. 81, 302-313.
41. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and, Czlonkowska A., (1998) Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Immunopharmacology 39, 167-180.
42. Lenzi G. L., Jones T., Reid J. L., and, Moss S., (1979) Regional impairment of cerebral oxidative metabolism in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 42, 59-62.
43. Lewis M. M., Smith A. B., Styner M., et al,. (2009) Asymmetrical lateral ventricular enlargement in Parkinson's disease. Eur. J. Neurol. 16, 475-481.
44. Lundblad M., Picconi B., Lindgren H., and, Cenci M. A., (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16, 110-123.
45. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., and, Herkenham M. A., (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464-467.
46. Meisingset T. W., Risa O., Brenner M., Messing A., and, Sonnewald U., (2010) Alteration of glial-neuronal metabolic interactions in a mouse model of Alexander disease. Glia 58, 1228-1234.
47. 13C nuclear magnetic resonance spectroscopy. J. Neurosci. Res. 79, 33-41.
48. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., Lanciego J. L., Artieda J., Gonzalo N., and, Olanow C. W., (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23, S8-S19.
49. Otsuka M., Ichiya Y., Hosokawa S., Kuwabara Y., Tahara T., Fukumura T., Kato M., Masuda K., and, Goto I., (1991) Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J. Neurol. Neurosurg. Psychiatry 54, 898-904.
50. Patel A. B., Rothman D. L., Cline G. W., and, Behar K. L., (2001) Glutamine is the major precursor for GABA synthesis in rat neocortex in vivo following acute GABA-transaminase inhibition. Brain Res. 919, 207-220.
51. Patel A. B., de Graaf R. A., Mason G. F., Kanamatsu T., Rothman D. L., Shulman R. G., and, Behar K. L., (2004) Glutamatergic neurotransmission and neuronal glucose oxidation are coupled during intense neuronal activation. J. Cereb. Blood Flow Metab. 24, 972-985.
52. Patel A. B., de Graaf R. A., Mason G. F., Rothman D. L., Shulman R. G., and, Behar K. L., (2005) The contribution of GABA to glutamate/glutamine cycling and energy metabolism in the rat cortex in vivo. Proc. Natl Acad. Sci. USA 102, 5588-5593.
53. 13C]-NMR. J. Cereb. Blood Flow Metab. 30, 1200-1213.
54. 13C]-NMR study to evaluate the efficacy of levodopa treatment in MPTP mouse model of Parkinson's disease, in Proc. Intl. Soc. Mag. Reson. Med., vol. 20. Salt Lake City, UT, 1980.
55. Pouclet H., Lebouvier T., Flamant M., Coron E., Neunlist M., Derkinderen P., and, Rouaud T., (2012) Autonomic nervous system as a source of biomarkers in Parkinson's disease. Presse Med. 41, 695-701.
56. Provencher S. W., (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30, 672-679.
57. Schmidt N., and, Ferger B., (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108, 1263-1282.
58. Schousboe A., Westergaard N., Waagepetersen H. S., Larsson O. M., Bakken I. J., and, Sonnewald U., (1997) Trafficking between glia and neurons of TCA cycle intermediates and related metabolites. Glia 21, 99-105.
59. Scotcher K. P., Irwin I., DeLanney L. E., Langston J. W., and, Di Monte D., (1990) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on ATP levels of mouse brain synaptosomes. J. Neurochem. 54, 1295-1301.
60. Sedelis M., Schwarting R. K., and, Huston J. P., (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125, 109-125.
61. Spokes E. G., (1979) GABA in Huntington's chorea, Parkinsonism and schizophrenia. Adv. Exp. Med. Biol. 123, 461-473.
62. Srinivasan R., Vigneron D., Sailasuta N., Hurd R., and, Nelson S., (2004) A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. Magn. Reson. Imaging 22, 523-528.
63. Tiwari V., and, Patel A. B., (2012) Impaired glutamatergic and GABAergic function at early age in AbetaPPswe-PS1dE9 mice: implications for Alzheimer's disease. J. Alzheimers Dis. 28, 765-769.
64. Tkac I., Starcuk Z., Choi I. Y., and, Gruetter R., (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn. Reson. Med. 41, 649-656.
65. Tristao F. S., Amar M., Latrous I., Del-Bel E. A., Prediger R. D., and, Raisman-Vozari R., (2013) Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease. Neurotox. Res. doi: 10.1007/s12640-013-9401-8.
66. Turner R. S., (2009) Basal Ganglia and The Regulation of Movement, in Encyclopedia of Life Sciences. John Wiley & Sons Ltd, Chichester.
67. Waniewski R. A., and, Martin D. L., (1998) Preferential utilization of acetate by astrocytes is attributable to transport. J. Neurosci. 18, 5225-5233.